PTO/SR/30 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number. Request 10/573 450 Application Number for January 19, 2007 Filing Date Continued Examination (RCE) Ken Takahashi First Named Inventor Transmittal Address to: 1747 Art Unit Mail Stop RCF Commissioner for Patents Knable, Geoffrey L. Examiner Name P.O. Box 1450 Alexandria, VA 22313-1450 Attorney Docket Number 4386.74850 This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2 Submission required under 37 CFR 1.114 Note; If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s). Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. Consider the arguments in the Appeal Brief or Reply Brief previously filed on ____ Enclosed ✓ Amendment/Reply Information Disclosure Statement (IDS) Affidavit(s)/ Declaration(s) Miscellaneous Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of ______ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 07-2069 , I have enclosed a duplicate copy of this sheet. ✓ RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) Other any other required fees Check in the amount of \$ ____ enclosed Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card Information and authorization on PTO-2038. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED Signature January 13, 2011 James K. Folker Name (Print/Type) Registration No. 37 538 CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facumille transmitted to the U.S. Patent and Trademark Office on the date shown below. Signature is collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTC to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete,

This collection of Information is required by 37 CFR 1.114. The Information is required to obtain or retain a benefit by the public which is to fie (and by the USPTO to process) an application. Confidentially is govered by 33 U.S. C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 Timutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time upon require to complete this form androis suggestions for reducing this turned, should be sent to the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenark Office, U.S. Desparing of the Chief Information CHI. S. Patient and Trajdenary Office Information CHI. S. Patient Information C